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Multi-drug resistant tuberculosis (MDR-TB) is 
defined as TB that is resistant to the two main first-
line drugs (isonaiazid and rifampicin). 
Extensively drug resistant TB  (XDR -TB) is a 
relatively rare type of MDR-TB and is defined as TB 
which is resistant to isonaiazid and rifampicin, plus 
resistant to any fluoroquinolone and at least one of 
three injectable 2nd line drugs (i.e. amikacin, 
kanamycin or capreomycin). 
Study Design  
Setting: Abu-Anja Teaching Hospital for Respiratory 
diseases.  
Period: January to September 2008. 
Rationale for the study 
It has been noted that there is a rapid increase in the 
number of patients who have completed first line 
anti-tuberculous drugs once or more, but their 
sputum remain heavily positive with Mycobacteria, 
while others have empirically started 2nd line 
treatment. 
Specific objectives  
1. To find out if these cases are MDR-TB, and to 
record the trend and the percentage of MDR-TB 
at Abu-Anja Hospital during this period.  
2. To find out the reasons for development of 
MDR-TB among these patients.  
3. To asses the number of the patients on 2nd line 
treatment before culture and sensitivity, and how 
they procure the drugs. 
4. To find out if there are cases resistant to 2nd line 
drugs.  
5. To assess the size of co-infection (HIV/TB etc.) 
in the study group.  
Materials and methods 
An exploratory, descriptive & analytic retrospective 
and prospective study of: 
 All patients who had been treated with 1st line 
anti-tuberculous drugs and whose sputum 
remains positive, and those who have started the 
2nd line treatment. 
An instructed questionnaire was used, with 24 open-
end questions, 10 multi-choice questions and 2 
comments. Each patient attempted to answer all the 
questions. 
Exclusion criteria: Patients who have defaulted, but 
whose sputum is negative for AAFB (acid alcohol 
fast bacilli), or whose drug sensitivity test remains 
sensitive to both Refampicin and Isoniazihydrazide 
(INH). 
Results 
Details of the 24 MDR-TB patients questioned 
 17 (71%) were males and 7 (29%) were females. 
 Marital status: Single 44%; Married men 33%; 
Divorced 6%; Housewives 17%. 
 Numbers in each age group: 20-30 years 10; 31-
40 years 6; 41-50 years 5; 51-60 years 3. 
 Occupation: Self-employed 33%; Jobless 13%; 
Student 4%; Housewife 17%; Farmer 29%; 
Government employee 4%. 
Compliance and defaulting 











1st line drugs 9 4 6 
2nd line drugs 6 5 13 
 
Reasons for TB treatment interruptions: No money, 
no drugs, felt well. 
 




31-40 years 41-50 years 51-60 
years 
Complied 2 2 1 3 
Defaulted 7 2 1 0 
Others 3 1 2 0 
MDR-TB numbers and trends at Abu-Anja 
Teaching Hospital 
Numbers of MDR-TB cases by year: 2004  0; 2005 4; 
2006  4; 2007 7; 2008 9. 
Evaluation of 11 case cohort from 2005-2007: Died 
2; Treated and hearing disability 2; Treated 
completely 3; Loss to follow up 4 (1 died without 
sputum conversion). 
MDR-TB cases from January-September 2008 
Of the 24 cases 21(88%) were MDR-TB only; 1 (4%) 
was MDR-TB+HIV and 2 (8%) were MDR-TB+ 
DM (diabetes mellitus). 
Table 3. Sensitivity test to 1ST line TB drugs 
 INH Refampicine Streptomycin Ethambuto
l 
Sensitive 0 2 1 4 
Resistant 24 22 23 20 
Conclusions 
  The MDR-TB trend is rapidly rising. 
  The MDR-TB situation at Abu-Anja hospital is 
the tip of an iceberg. The number of patients 
will increase if 2nd line drugs are available free of 
charge. 
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 This reflects previous poor management of TB 
at different levels. 
 The study is small, but reflects serious indicators. 
Recommendations 
1. To revisit the DOTS package strategy, and to 
strengthen and implement it to reach those who 
are difficult to reach (i.e. they have no access to 
medical facilities). This should prevent more 
patients becoming cases of MDR-TB. 
2. Early monitoring of MDR-TB to contain its 
spread, by providing services free of charge (e.g. 
sputum culture and drug sensitivity test of 2nd 
line drugs which should be sustained and free of 
charge). 
3. Urgent training of a task force for management 
of MDR-TB in the South Sudan. 
4. Urgent TB-survey of South Sudan to discern the 
magnitude of the problem. 
  
  Closing note:  
At the launching of JUBA INITIATIVE on HIV in 
2003, I said, “this war is; 
 A war against an invisible enemy. 
 A war in which no wounded soldiers survive.  
 A war in which there are no warlords to 
negotiate with.  
 A war in which no people of goodwill are 
effective. 
 A war in which no one should turn back, 
because it is directed against US ALL.” 
Now this invisible ENEMY becomes faster and 
more LETHAL in presence of MDR-TB. 
 












The theme of World Breastfeeding Week (1 to 7 
August) was "Breastfeeding - a vital emergency 
response. Are you ready?”  
 
It highlights the need to protect, promote and 
support breastfeeding in emergencies for infant and 
young child survival, health and development.  
As part of emergency preparedness, hospitals and 
other health care services should train health workers 
to help mothers establish breastfeeding and/or 
overcome difficulties. 
 
WHO recommends exclusive breastfeeding until 
a baby is six months old, and continued 
breastfeeding with the addition of nutritious 
complementary foods for up to two years or 
beyond.  
 
